Tvardi Therapeutics is trading at $1.70 (+5.59%) amid broader risk-on sentiment.
- No clearly reported company-specific announcement emerged on September 22, 2026; the latest visible company news remains the July 30 TTI-109 ulcerative-colitis update.
- The Nasdaq is up 0.51%, while easing yields are supporting equities.
- Earlier September investor events and analyst coverage are stale catalysts, so attribution remains tentative.